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51 Impact on physiotherapy workload at the Leeds Regional
Paediatric CF Unit following the ﬁrst full year of the UK National
CF Screening Programme
R. Ball1, K. Brownlee1, T. Lee1, S. Conway1. 1St James’s Hospital, Leeds, United
Kingdom
There is increasing consensus that early identiﬁcation of CF by neonatal screening
results in improved outcomes. Infants require early intensive specialist input if the
beneﬁts of early diagnosis are to be realised.
The Leeds Regional Paediatric CF Unit (LRPCFU) has screened babies born in
Leeds for CF since 1975. From the beginning of 2007 all babies born in Yorkshire
have been screened for CF using the National CF Screening Protocol (NCFSP). The
NCFSP is prescriptive on how, and by whom, the diagnosis should be delivered,
and where children should ideally receive care. Specialist Centres and experienced
staff are central to this process. A typical UK District General Hospital expects no
more than 1 diagnosis a year.
We present a retrospective audit of the impact of these changes on the workload of
the LRPCFU. In 2007 16 newly diagnosed infants (8 Leeds & 8 non-Leeds) were
referred to our unit compared to a median per year of 3 (range 0−5) from 1998 to
2006.
Changes in referral pathways have been associated with an increased number of
babies with Meconium Ileus being cared for at the LRPCFU, 7 in 2007 vs a previous
maximum of 2 per year.
For the 16 infants there were 24 inpatient admissions contrasting to a median of 2
per year from 1998–2006. Inpatient physiotherapy contacts during these admissions
was 496 in 2007 vs a previous median per year of 44 (1998–2006). Outpatient
physiotherapy contacts also increased, 76 vs 12.
The treatment of a newly diagnosed baby and education of their family requires
considerable time from all members of the CF team. If the increase seen by our unit
in the ﬁrst year of NCFSP is predictive of the future then there must be appropriate
targeted funding to ensure that these children receive optimal care and outcome.
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screening
V. Skalicka1, D. Zemkova1, T. Fischerova1, L. Pelikan1, F. Votava2, V. Vavrova1.
1National CF Centre, University Hospital Motol, Prague, Czech Republic; 2Dept
of Paediatrics, University Hospital K. Vinohrady, Prague, Czech Republic
Within the Czech pilot CF newborn screening (NBS) project (2/2005−11/2006) 11
neonates fulﬁlling the criteria of CF were diagnosed. 9 of them are followed up at the
Prague CF centre, 1 had meconium ileus (MI). The control group comprises of 18
non-screened patients born 2004–2007, diagnosed according to clinical symptoms.
We compared anthropometric data and costs of care of 8 NBS patients and 16
patients from the control group (C) using F-test and t-test. MI patients were
excluded.
The median age at diagnosis was 0.1 year in NBS patients and 1 year (0.2−2.8
years) in the control group. The period of follow up and care did not signiﬁcantly
differ in either group (median 1.5 years versus 1 year).
The total average cost of care in the NBS group was 37,659CZK (30,754–
57,251CZK), which is an average of 29,691CZK (19,217–40,410CZK) per year.
In the control group the total average cost of care was 125,258CZK (18,124–
622,020CZK) which is an average of 84,760CZK (21,480–806,482CZK) per year.
There was a much greater variation of cost of care in the control group and the
cost of care per patient was much higher (total p = 0.006, per year p = 0.011). The
patients did not signiﬁcantly differ in body length: NBS −0.5±0.6 SD versus C
−0.9±0.9 SD. However NBS patients had a better nutritional status at the latest
examination: body weight NBS −0.2±0.6 SD versus C −1.4±1.4 SD (p = 0.03) and
BMI 0.2±0.6 vs −0.7±1 SD (p = 0.03).
Patients diagnosed with NBS have a better nutritional status and lower costs of care
than patients diagnosed according to clinical symptoms during the same period.
Supported by: VZ 64203–6405.
53 Results of DNA-based cystic ﬁbrosis newborn screening
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As newborn screening (NBS) for cystic ﬁbrosis (CF) has expanded during recent
years, many laboratories screening for CF include both biochemical and molecular
testing with DNA analyses of CFTR mutations. With the growing need for a
proﬁciency testing (PT) program for molecular testing, the Centers for Disease
Control have created a repository of CFTR mutations using human blood specimens.
PT panels consisting of 5 to 7 coded specimens from adult CF or CF carrier donors
were sent quarterly to NBS laboratories worldwide with instructions to report the
genotype, method used, and the presumptive clinical assessment of each specimen.
As of 1/1/2008, there were XX participants using 16 different methods for DNA
analysis. Due to the variety in mutation panels, laboratories were evaluated based
on clinical assessments. Mutations that were not included in a panel were not
evaluated. Overall, the laboratories performed well. Data compiled from 4 quarters
showed that there were 336 (69%) correct assessments, 13 (3%) incorrect clinical
assessments, and 8 (2%) ampliﬁcation failures. There were 128 (26%) specimens
that were not evaluated. Most recently, we completed PT assessment with blood
spots from a homozygous F508del donor, and an F508del carrier spiked with IRT in
an actual simulation of a NBS test. Developing a PT program for DNA-based testing
is complicated by the number of methods and different alleles each laboratory
chooses to test. Although molecular testing for CF may be complex, PT can monitor
the laboratory’s ability to test multiple alleles, including uncommon alleles, the
limitations of various assays, and the different algorithms used for screening.
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Objectives: Observe biochemical hepatic enzymes evolution of the CF newborn
diagnosed by screening (starting 07/01/03), from diagnosis until 06/30/07, admitted
to this Center; compare clinical manifestations, in the ﬁrst year of age and follow
the evolution of the above mentioned hepatic enzymes.
Methods: Analysis of medical records of 59 patients diagnosed as CF in 4 years.
Outcomes recorded at the time of diagnosis: age, sex, gestational age, birth weight,
nutritional status, mutations, meconium ileum, pancreatic insufﬁciency, neonatal
jaundice, respiratory manifestations, edema, size of liver, level of serum albumin,
hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT),
gama-glutamyl transferase (GGT) and alkaline phosphatase (ALP). For comparative
analysis between patients, 5 were excluded (lack of information).
Results: 31/59 (52.5%) children were male. 6.5% were premies and 12% had low
birth weight. Median age of diagnosis was 1.3 months. 64.4% presented D F508
mutation. 13.8% had meconium ileum. Respiratory manifestations were present in
12%. 23.5% were malnourished: moderate to severe (−2 SD, Z score). 43/59
(73%) had pancreatic insufﬁciency. Almost half of them had hipoalbuminemia at
the diagnosis. 39/54 (72%) presented at least one biochemical elevation. This was
observed in ALP 46% (25/54) and in GGT 33% (18/54). By the end of one year
of age, 27/39 (69%) had normal hepatic enzymes.
Conclusions: Hepatic enzymes were elevated in 72% of CF children diagnosed by
neonatal screening, and these enzymes normalized in 69% children by one year
of age.
